Cadence gets mixed results for IV pain drug

Cadence Pharmaceuticals is reporting mixed results from two Phase III trials of Acetavance, an intravenous version of acetaminophen. One trial missed its primary endpoint of reducing pain intensity levels over 48 hours. That particular study did, however, meet several secondary endpoints. A second trial of Acetavance met its primary endpoint, demonstrating a statistically significant reduction of fever over six hours compared to a placebo. Investors didn't take kindly to the mixed results, sending Cadence's shares down--plunging 28 percent in pre-market trading.

- see this release from Cadence

Suggested Articles

Vital strategies for steriles development to ensure more flexibility within drug development.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.

Operation Warp Speed is living up to its name as AstraZeneca is teaming up with IQVIA to boost its R&D for its pandemic shot.